The majority of APIs in development have properties that cause significant issues when creating a formulation for oral administration: a high melting point and/or low solubility. A high melting point makes it impossible to use hot melt extrusion to create a solid dispersion, while a low solubility in appropriate solvents makes a variety of formulation techniques difficult and costly to use, such as spray drying or emulsification. SeraNovo has devised a novel formulation technology, opening up the way to the market for these notorious APIs. This page explains the concept of our technology and our approach to increasing oral bioavailability.
A mixture of two or more solid components exerting a melting point that is lower than each of the two constituents is called a eutectic mixture. Effectively one component prevents the other from crystallizing, keeping the mixture a liquid. This effect usually arises from specific hydrogen bonding between the two entities, causing a specific molar ratio to be optimal for the eutectic composition (see figure on the right for a eutectic phase diagram). These interactions can be so effective that certain ‘’Brick Dust APIs’’ with melting points >300°C can be a liquid at room temperature with beneficial characteristics such as a low volatility and a high loading capacity. As the interactions between the two components mainly consist of hydrogen bonds, they are broken up easily when the mixture is exposed to water leading to a fast dissolution of the formulation in the stomach. The picture below shows a schematic representation in comparison with well-known systems.
The eutectic mixture is created by using a variety of non-toxic and safe constituents which are either pharmaceutically acceptable or GRAS (Generally Recognized As Safe by the FDA). SeraNovo has a library of hundreds of constituents that satisfy safety criteria and can make endless unique combinations, optimised to fit your API perfectly in terms of performance and stability. Our library includes many types of solid and liquid excipients, such as polymers, sugars, organic acids, nutritional compounds, metabolites and food additives.
An API has a high melting point when it is energetically favoured to maintain its crystal lattice. A lot of energy is required to break the crystal lattice, thus leading to a very slow dissolution when such a crystal is exposed to gastric fluids. However, in a eutectic mixture this crystal lattice has already been broken apart. So, when the eutectic mixture encounters gastric fluids, the water molecules quickly disintegrate the hydrogen bond network of the eutectic mixture. This causes a very rapid dissolution, usually far above the equilibrium solubility. This is called the ‘’Spring’’. The API is now in solution far above its equilibrium solubility, prone to recrystallization. This is where polymeric constituents play their part: they prevent fast recrystallization of the API in intestinal fluids. This is called the ‘’Parachute’’. The Parachute ensures a high concentration is maintained in the absorptive environment of the intestines. The dissolution graph on the right shows this mechanism using one of our formulations of a very poorly soluble, basic API.
SeraNovo’s proprietary platform technology provides you with the option of a liquid formulation, a solid formulation (also called a ‘’Glass’’) or both. The Glass formulations are dehydrated eutectic mixtures, liquifying upon contact with water. This provides enhanced stability as well as a higher drug load whilst keeping the production costs low in relation to conventional solid formulation production costs (e.g. spray drying). The table below highlights the various advantages compared to a conventional formulation technology, the Amorphous Solid Dispersion. The figure shows a schematic representation of what two finished DES dosage forms could look like.
- Suitable for high melting point, low solubility APIs
- Increased solubility and bioavailability
- Simple production scale-up
- Short development time